MGMT and central nervous system cancer: Previous studies showed that patients with MGMTmet with grade II or III glioma or glioblastoma have a longer overall survival compared with those with unmethylated MGMT promoter (MGMTunmet) (Binabaj et al., 2018; Schaff et al., 2020; Haque et al., 2021, 2022).